摘要
目的:探讨拓扑替康(topotecan,TPT)联合顺铂(DDP)治疗小细胞肺癌(smallcelllungcancer,SCLC)的疗效。方法:35例初治SCLC患者应用TPT1mg/(m2·d),静脉滴入30min;联合DDP20mg/(m2·d),静脉滴入,连用5d,每3周为1个周期,2~3个周期后评价疗效和不良反应。结果:TPT与DDP联合用于初治SCLC有效率为74.3%(26/35),其中CR20.0%(7/35),PR54.3%(19/35)。主要不良反应为骨髓抑制,其中Ⅲ~Ⅳ度中性粒细胞缺乏为54.3%(19/35),Ⅲ~Ⅳ度血小板下降为34.3%(12/35),Ⅲ~Ⅳ度血红蛋白下降为20.0%(7/35),非血液学毒性较轻。结论:TPT联合DDP是治疗SCLC疗效较好方案,主要不良反应为血液学毒性。
OBJECTIVE: To investigate the efficacy and toxicity of topotecan plus cisplatin in the treatment of small-cell lung cancer (SCLC). METHODS: Thirty-five previously untreated patients with SCI.C received the combined chemotherapy of topotecan and cisplatin, topotecan 1 mg/(m^2 · d), iv infusion for 5 days; cisplatin 20 mg/(m^2 · d), iv infusion for 5 days, reapeated every 21 days. Assessment was given after 2 or 3 cycles. RESULTS: CR was in 7 cases (20.0%),PR 19 cases(54.3%), and the overall response rate was 74.3%(26/ 35). The main side effect was myelosuppression, and Grade Ⅲ-Ⅳ neutropenia , thrombopenia and anemia were 54.3 % ( 19/ 35), 34.3% (12/35), 20.0% (7/35) respectively. CONCLUSIONS:Topotecan plus cisplatin is a better regimen for the treatment of SCLC, and the main toxicity of this regimen is hematological toxicity.
出处
《肿瘤防治杂志》
2005年第17期1325-1326,共2页
China Journal of Cancer Prevention and Treatment
关键词
癌
小细胞/药物疗法
肺肿瘤/药物疗法
托泊替康
顺铂
carcinoma, small cell/drug therapy
lung neoplasms/drug therapy
topotecan, cisplatin